NCT00251732View on ClinicalTrials.gov

Role of Pain Modulation in GERD Patients Who Failed Standard Dose Proton Pump Inhibitors (PPI)

PHASE4CompletedINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

March 31, 2005

Primary Completion Date

May 31, 2010

Study Completion Date

May 31, 2010

Conditions
Gastroesophageal Reflux Disease
Interventions
DRUG

Standard dose (once daily) PPI plus low-dose antidepressant

20 mg. rabeprazole plus low dose tricyclic antidepressant(TCA)

DRUG

Double dose PPI plus evening placebo

20 mg. twice daily with a placebo

DRUG

Rabeprazole , placebo, placebo

20 mg rabeprazole(PPI) once daily -a.m. placebo -p.m. placebo -bedtime

Trial Locations (1)

85723

Southern Arizona VA Health Care System, Tucson

All Listed Sponsors
collaborator

Southern Arizona VA Health Care System

FED

collaborator

Janssen Pharmaceutica N.V., Belgium

INDUSTRY

lead

University of Arizona

OTHER

NCT00251732 - Role of Pain Modulation in GERD Patients Who Failed Standard Dose Proton Pump Inhibitors (PPI) | Biotech Hunter | Biotech Hunter